Results 31 to 40 of about 81,753 (307)
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity [PDF]
, 2016 Background: Histone deacetylase inhibitors (HDACi) exert multiple cytotoxic actions on cancer cells. Currently, different synthetic HDACi are in clinical use or clinical trials; nevertheless, since both pro-invasive and anti-invasive activities have been
Andrade, Ricardo +6 more
core +4 more sources
Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer [PDF]
, 2020 Increased numbers of myeloid-derived suppressor cells (MDSCs) are positively correlated with poor prognosis and reduced survivals of cancer patients. They play central roles in tumor immune evasion and tumor metastasis.
Abu Nada, M +9 more
core +3 more sources
Nanomaterials as potential transporters of HDAC inhibitors
Medicine in Drug Discovery, 2020 Nanomedicine that combines technology with medical diagnostics and therapeutics is now advancing to greater heights for its significant potential in drug delivery.
Cristabelle De Souza +3 more
doaj +1 more source
Effects of the histone deacetylase inhibitor valproic acid on human pericytes in vitro. [PDF]
PLoS ONE, 2011 Microvascular pericytes are of key importance in neoformation of blood vessels, in stabilization of newly formed vessels as well as maintenance of angiostasis in resting tissues.
Jakob Karén +5 more
doaj +1 more source
Evaluation of histone deacetylase inhibitory and antiproliferative activity of piperine and its derivatives [PDF]
Songklanakarin Journal of Science and Technology (SJST), 2022 Piperine (1) was obtained from the seeds of Piper nigrum L. It could act as a pan-histone deacetylase (HDAC) inhibitor. This lead compound was structurally modified to six derivatives that exhibited improved HDAC inhibitory activity.
La-or Somsakeesit +6 more
doaj +1 more source
Quinolone-based HDAC inhibitors
Journal of Enzyme Inhibition and Medicinal Chemistry, 2013 HDAC inhibitors emerged as promising drug candidates in combating wide variety of cancers. At present, two of the compounds SAHA and Romidepsin were approved by FDA for cutaneous T-cell lymphoma and many are in various clinical phases. A new quinolone cap structure was explored with hydroxamic acid as zinc-binding group (ZBG).
Gopalan, Balasubramanian +5 more
openaire +2 more sources
Current HDAC Inhibitors in Clinical Trials
CHIMIA, 2022 Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets.
Elisabetta Di Bello +3 more
openaire +4 more sources
Frontiers in Immunology, 2018 Histone deacetylases (HDAC) are one of the key epigenetic modifiers that control chromatin accessibility and gene expression. Their role in tumorigenesis is well established and HDAC inhibitors have emerged as an effective treatment modality.
Sajad A. Bhat +5 more
doaj +1 more source
Translational Oncology, 2021 Cancer cell phenotypes evolve during a tumor's treatment. In some cases, tumor cells acquire cancer stem cell-like (CSL) traits such as resistance to chemotherapy and diminished differentiation; therefore, targeting these cells may be therapeutically ...
Feng Chi +10 more
doaj +1 more source
HDACs and HDAC Inhibitors in Cancer Development and Therapy [PDF]
Cold Spring Harbor Perspectives in Medicine, 2016 Over the last several decades, it has become clear that epigenetic abnormalities may be one of the hallmarks of cancer. Posttranslational modifications of histones, for example, may play a crucial role in cancer development and progression by modulating gene transcription, chromatin remodeling, and nuclear architecture.
Yixuan, Li, Edward, Seto
openaire +2 more sources